Ma Jiachi, Sun Xiaowen, Guo Tiankang, Su He, Chen Quan, Gong Zhenqiang, Qi Jianbo, Zhao Xiaodan
Department of General Surgery, Gansu Provincial People's Hospital, LanZhou.
Department of Dermatology, The First Hospital of Tianshui, Tianshui.
Cancer Manag Res. 2017 Oct 9;9:481-493. doi: 10.2147/CMAR.S147699. eCollection 2017.
This article investigates the relationship between cancer cells and stromal cells in carcinoma cell living microenvironment and elucidates the mechanism that interleukin-1 receptor antagonist (IL-1RA) blocks metastatic potential in colon cancer.
Western blot and RT-PCR assay were used to determine the expression of hepatocyte growth factor (HGF) and IL-1α in colon carcinoma cells and stromal cells. Effect of IL-1RA and HGF on metastatic potential of colon cancer cells were examined by proliferation, invasion, and angiogenesis assays. The interactional role of IL-1RA and HGF were detected by ELISA assay, invasion, and angiogenesis assay making up a co-culture system consisting of stromal and colon cancer cells in cells living microenvironment.
IL-1α was expressed in human umbilical vein endothelial cells (HUVECs) and HT-29 and WiDr (colon cancer cell lines with higher liver metastatic potential). HGF was expressed only in fibroblast. HGF secretion from fibroblasts was significantly inhibited by IL-1RA (<0.01). Furthermore, IL-1RA could significantly inhibit migration, proliferation, and angiogenesis of HUVECs (<0.01). In the double co-culture system, there is a high liver metastatic potential of colon cancer cell line (HT-29) because it can secrete autocrine IL-1α, significantly enhanced angiogenesis compared with low liver metastatic cell line (CaCo-2) (<0.01), which does not secrete IL-1α. On the contrary, blockage of autocrine IL-1α by IL-1RA might significantly decrease metastatic potential of colon carcinoma cells through downregulation of IL-1α/PI3K/NF-κB pathway.
IL-1 receptor antagonist (IL-1RA) is an important inhibitor in metastatic process of colon carcinoma cell. Based on the above results, we suggest that IL-1RA may be a promising new therapeutic approach in inhibiting colon cancer with IL-1-producing patients.
本文研究癌细胞与癌细胞生存微环境中基质细胞之间的关系,并阐明白细胞介素-1受体拮抗剂(IL-1RA)阻断结肠癌转移潜能的机制。
采用蛋白质免疫印迹法和逆转录聚合酶链反应(RT-PCR)检测结肠癌细胞和基质细胞中肝细胞生长因子(HGF)和IL-1α的表达。通过增殖、侵袭和血管生成实验检测IL-1RA和HGF对结肠癌细胞转移潜能的影响。在细胞生存微环境中,构建由基质细胞和结肠癌细胞组成的共培养体系,采用酶联免疫吸附测定(ELISA)、侵袭和血管生成实验检测IL-1RA和HGF的相互作用。
IL-1α在人脐静脉内皮细胞(HUVECs)以及HT-29和WiDr(具有较高肝转移潜能的结肠癌细胞系)中表达。HGF仅在成纤维细胞中表达。IL-1RA可显著抑制成纤维细胞分泌HGF(<0.01)。此外,IL-1RA可显著抑制HUVECs的迁移、增殖和血管生成(<0.01)。在双重共培养体系中,具有高肝转移潜能的结肠癌细胞系(HT-29)可分泌自分泌IL-1α,与不分泌IL-1α的低肝转移细胞系(CaCo-2)相比,其血管生成显著增强(<0.01)。相反,IL-1RA阻断自分泌IL-1α可能通过下调IL-1α/PI3K/NF-κB通路显著降低结肠癌细胞的转移潜能。
白细胞介素-1受体拮抗剂(IL-1RA)是结肠癌细胞转移过程中的重要抑制剂。基于上述结果,我们认为IL-1RA可能是治疗IL-1分泌型结肠癌患者的一种有前景的新治疗方法。